Skip to main content

Table 2 Impact of the presence of a shared epitope on DAS28-ESR remission at week 24 in a multivariable conditional logistic regression analysis

From: Impact of the HLA-DRB1 shared epitope on responses to treatment with tofacitinib or abatacept in patients with rheumatoid arthritis

  OR 95% CI p value
Tofacitinib 1.473 0.291–7.447 0.639
Abatacept 25.881 3.140–213.351 0.0025
  1. The relationship between shared epitope (SE) positivity and DAS28-ESR remission was analyzed using a conditional logistic regression model adjusted for age, sex, RA disease duration, biologic-naïve, ACPA titer, ΔDAS28ESR HAQ-DI, and PS at baseline
  2. ACPA anticitrullinated peptide antibody, ΔDAS28-ESR, delta DSA28-ESR, indicating the magnitude of changes from baseline to week 4 in DAS28-ESR; DAS28-ESR, Disease Activity Score in 28 joints using the erythrocyte sedimentation rate. HAQ-DI Health Assessment Questionnaires Disability Index, PS propensity score, RF rheumatoid factor, SE shared epitope